Dae Gon Ha
Stock Analyst at Stifel
(2.38)
# 2,427
Out of 5,182 analysts
55
Total ratings
35.56%
Success rate
4.48%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $98 → $125 | $94.06 | +32.89% | 6 | Feb 26, 2026 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.36 | +273.13% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $3.06 | -1.96% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $52.76 | +40.26% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $7.44 | -59.68% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $13.20 | +384.85% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $269.27 | -18.30% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $24.53 | +417.73% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.43 | +1,299.42% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.69 | +387.80% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $2.05 | +241.46% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.24 | +407.81% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $84.18 | -70.30% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.49 | +10.42% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $30.98 | +819.95% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.48 | +1,251.35% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.82 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $40.99 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.86 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.67 | +618.56% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $20.80 | +2,255.77% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $125
Current: $94.06
Upside: +32.89%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.36
Upside: +273.13%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $3.06
Upside: -1.96%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $52.76
Upside: +40.26%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $7.44
Upside: -59.68%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $13.20
Upside: +384.85%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $269.27
Upside: -18.30%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $24.53
Upside: +417.73%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.43
Upside: +1,299.42%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.69
Upside: +387.80%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $2.05
Upside: +241.46%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.24
Upside: +407.81%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $84.18
Upside: -70.30%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.49
Upside: +10.42%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $30.98
Upside: +819.95%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.48
Upside: +1,251.35%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.82
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $40.99
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $8.86
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.67
Upside: +618.56%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $20.80
Upside: +2,255.77%